ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Authors
Category Primary study
ConferenceUnited European Gastroenterology Journal
Year 2022
This article has no abstract
Epistemonikos ID: 27d1dbb7c31ef3d691f7c663d2116d2e3406ff69
First added on: Apr 30, 2026